(Q34615021)

English

MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

evasion of host immune response

1 reference

based on heuristic

inferred from title

papillary thyroid cancer

1 reference

based on heuristic

inferred from title

Trevor E Angell

object named as

Trevor E Angell

1

0 references

Melissa G Lechner

object named as

Melissa G Lechner

2

0 references

author name string

Julie K Jang

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Jonathan S LoPresti

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Alan L Epstein

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

7 October 2014

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

6034-6044

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

RNA sequencing identifies multiple fusion transcripts, differentially expressed genes, and reduced expression of immune function genes in BRAF (V600E) mutant vs BRAF wild-type papillary thyroid carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Cancer statistics, 2013

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

"Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Changes of apoptosis, p53, and bcl-2 by irradiation in poorly differentiated thyroid carcinoma cell lines: a prognostic marker for the prospect of therapeutic success?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Interferon induced thyroiditis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

How tumours escape mass destruction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

MHC class I antigens and immune surveillance in transformed cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-bound immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Mutations of the BRAF gene in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

MHC antigens and tumor escape from immune surveillance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

A phase I trial of recombinant gamma interferon in patients with cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Thyroiditis after treatment with interleukin-2 and interferon alpha-2a

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

7 July 2018

Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimotos thyroiditis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

26 October 2018

Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

26 October 2018

Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

26 October 2018

The immune score as a new possible approach for the classification of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

26 October 2018

Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

26 October 2018

Chimeric TNT-3 Antibody/Murine Interferon-γFusion Protein for the Immunotherapy of Solid Malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

26 October 2018

Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

26 October 2018

Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4252612

26 October 2018

Expression of ICAM-1, B7.1 and TPO on human thyrocytes induced by IFN-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/25294906

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid

1 reference

https://pubmed.ncbi.nlm.nih.gov/25294906

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-gamma induces HLA-DR expression by thyroid epithelium

1 reference

https://pubmed.ncbi.nlm.nih.gov/25294906

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improving the therapeutic index of IL-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/25294906

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25294906

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infiltration of a mixture of different immune cells may be related to molecular profile of differentiated thyroid cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25294906

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-14-0879

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34615021&oldid=1644379222"